First Name: Jean
Last Name: Nakamura
Institution: University of California, San Francisco
Address 1: 1450 Third Street
Address 2: Room 231
City: San Francisco
State/Province: California
Country: USA
Zip: 94158
Phone: 415 710-8276
Alternate Phone: 415 353-8950
Email: jnakamura@radonc.ucsf.edu

Requirements to submit AOI:

A comprehensive review of previously published data has been completed.: Yes
The specific aims are clear and focused.: Yes
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator.: Yes
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months.: Yes

---

Project Title: Genetic Alterations in Second Malignant Neoplasms
Planned research population (eligibility criteria): tissue samples of the following types of second malignant neoplasms would be analyzed: breast, meningioma, other CNS, sarcoma, leukemia and bone
Proposed specific aims: 1. To identify patterns of genetic losses and gains in human SMNs 2. To determine whether these patterns of genetic alterations in clinical SMNs correlate to genetic alterations found in mouse models of SMNs The long term goal of this work is to define the genetic mechanisms underlying the development of SMNs in cancer survivors.
Will the project require non-CCSS funding to complete?: Yes
If yes, what would be the anticipated source(s) and timeline(s) for securing funding?: Initial work could be funded from my current funds, but completion would require additional funding. My collaborators and I will apply for funding from the NCI, DOD and other private funding sources. I anticipate that applications would be submitted in 2011, and funding would be secured in late 2011 or 2012.

Does this project require contact of CCSS study subjects for . . .

Additional self-reported information: No
Biological Samples: Yes
Medical record data: No
If yes to any of the above, please briefly describe.: In order to perform loss of

heterozygosity analysis, matched normal control DNA would be needed for each SMN specimen. If normal control DNA were not already archived by the CCSS, it may be necessary to contact CCSS study subjects to obtain normal tissue control, which could be peripheral blood or buccal swabs.

What CCSS Working Group(s) would likely be involved? (Check all that apply)

Second Malignancy: Secondary
Chronic Disease:
Psychology / Neuropsychology:
Genetics: Primary
Cancer Control:
Epidemiology / Biostatistics:

To describe the anticipated scope of the study, please indicate the specific CCSS data to be included as outcome (primary or secondary) or correlative factors. (Check all that apply)

Late mortality: Secondary,Correlative Factors
Second Malignancy: Primary

Health Behaviors

Tobacco:
Alcohol:
Physical activity:
Medical screening:
Other:
If other, please specify:

Psychosocial

Insurance:
Marriage:
Education:
Employment:
Other:
If other, please specify:

Medical conditions

Hearing/Vision/Speech:
Hormonal systems:
Heart and vascular:
Respiratory:
Digestive:

Surgical procedures:
Brain and nervous system:
Other:
If other, please specify:

Medications

Describe medications:

Pregnancy and offspring:
Family History: Correlative Factors

Psychologic/Quality of Life

BSI-18:
SF-36:
CCSS-NCQ:
PTS:
PTG:
Other:
If other, please specify:

Chronic conditions (CTCAE v3):
Health status:

Demographic

Age:
Race:
Sex:
Others:
If others, please specify:

Cancer treatment

Chemotherapy: Correlative Factors
Radiation therapy: Correlative Factors
Surgery:

Anticipated sources of statistical support

CCSS Statistical Center:
Local institutional statistician: Yes
If local, please provide the name(s) and contact information of the statistician(s) to be involved.: Adam Olshen, Ph.D. Director, Biostatics UCSF 1450 Third Street SF, CA 94158 olshena@biostat.ucsf.edu 415 514 9406
Will this project utilize CCSS biologic samples?: Yes

If yes, which of the following?

Buccal cell DNA: Yes
Peripheral blood:
Lymphoblastoid cell lines:
Second malignancy pathology samples: Yes
Other requiring collection of samples:
If other, please explain:

Other general comments: